Germany should cut gas use in preparation for Russian cut-off -research

Published by
Reuters UK

By Vera Eckert FRANKFURT (Reuters) – Germany should already limit gas use, even though Russian supplies have so far continued, to prepare for the possibility of a future cut-off in retaliation for Western sanctions over Moscow’s invasion of Ukraine, energy research institute EWI said on Monday. Russian energy giant Gazprom last Wednesday stopped gas supplies to Bulgaria and Poland after they declined to comply with a scheme proposed by Moscow requiring payments in roubles, raising concerns Germany could also be vulnerable. “Gas demand should be reduced immediately over the summer months,” said… Continue reading “Germany should cut gas use in preparation for Russian cut-off -research”

Cyprus also affected by energy prices despite not using natural gas, permanent secretary of Energy Ministry told meeting in Brussels

The European Union’s Energy Ministers discussed the energy situation in the European Union as a result of the Russian invasion of Ukraine and the next steps after Gazprom’s suspension of gas deliveries to Poland and Bulgaria, during an extraordinary meeting of the Transport, Telecommunications and Energy Council in Brussels on Monday.

Cyprus was represented by permanent secretary of the Ministry of Energy, Marios Panagides. Panagides explained during his intervention, that although Cyprus is the member state with the lowest dependence on Russian natural gas, it is nevertheless affected due to the significant increases in energy prices in general.

Panagides also said that Cyprus supports the measures promoted by the EU for its energy security, including the proposal for a Regulation on gas storage and an EU Platform for Common Procurement.

According to a statement from the Ministry of Energy, the member states expressed full solidarity and readiness to assist affected partners and exchanged views on securing the EU’s energy supply from reliable suppliers, on the transit of natural gas and the storage of gas reserves, particularly in view of the coming winter.

The level of EU preparedness, solidarity measures and possible emergency measures in relation to the EU energy supply situation were also discussed.

In his intervention Panagides also referred to the importance of exploiting the energy reserves of the member states, including the natural gas reserves of Cyprus, and highlighted Cyprus’ efforts to create synergies with Greece, Israel and Egypt.

Panagides also referred to the measures related to the Green Transition, pointing out that Cyprus supports these measures. He pointed out though that the different starting points of each member states must be taken into account.

Source: Cyprus News Agency

Cyprus Department of Meteorology – Forecast for the sea area of Cyprus (A)

CYPRUS DEPARTMENT OF METEOROLOGY

FORECAST FOR THE SEA AREA OF CYPRUS (A)

FOR THE PERIOD FROM 0600 03/05/2022 UNTIL 0600 04/05/2022

Area covered is 8 kilometers seawards.

Winds are in BEAUFORT scale. Times are local times.

Atmospheric pressure at the time of issue: 1010hPa (hectopascal)

Weak low pressure is affecting the area. ?he weather will be mainly fine with locally increased cloud coverage and risk of isolated rain showers from noon onward. Local mist or fog and low cloud during dawn. Dust in suspension.

Visibility: Good to moderate, locally poor

Sea surface temperature: 20°C

Warnings: NIL

AREA

PERIOD

WIND

STATE OF SEA

West Coast

Morning

Northeast to Southeast 4, at times locally 4

Smooth to Slight, at times locally Slight

Afternoon

West to Northwest 4, at times locally 4 to 5

Slight

Night

West to Northwest 4, at times locally 4 to 5

Slight

South Coast

Morning

Northeast to East 4, at times locally 4 to 5

Smooth to Slight, at times locally Slight

Afternoon

Northeast to East 4 to 5, gradually 3 to 4

Slight

Night

Northeast to East 3 to 4, later Southwest to Northwest

Slight

East Coast

Morning

Northeast 4, at times locally 4 to 5

Smooth to Slight, at times locally Slight

Afternoon

North to Northeast 4 to 5, gradually Northwest to Northeast 3 to 4

Slight

Night

Northwest to Northeast 3 to 4, gradually West to Northwest

Slight

North Coast

Morning

Northeast to East 4, at times locally 4 to 5

Smooth to Slight, at times locally Slight

Afternoon

Northeast to East 4 to 5, gradually Northwest to Northeast 3 to 4

Slight

Night

Northwest to Northeast 3 to 4, gradually Southwest to Northwest

Slight

Source: Cyprus News Agency

PRESS RELEASE – BW – Agendia to Deliver Robust Suite of Data Advancing Breast Cancer Care at ASCO 2022

Agendia to Deliver Robust Suite of Data Advancing Breast Cancer Care at ASCO 2022

Company showcases pipeline developments and sub-studies from the revolutionary FLEX Registry with posters focused on patient-centric insights

Two oral discussion sessions to focus on RUO ImPrint immune signature and BluePrint® whole transcriptomic analysis in Black women

IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)– Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, today announced it will present new data from ongoing clinical research evaluating its comprehensive genomic tests at the upcoming American Society of Clinical Oncology Annual Meeting (ASCO), taking place June 3-7, 2022 in Chicago, Illinois.

Data will highlight Agendia’s clinical focus on whole transcriptome analysis as well as breast cancer care for underserved populations, in addition to several sub-studies derived from the company’s FLEX Registry, the real-world, multicenter, prospective, observational breast cancer study. Two abstracts selected by ASCO for oral discussion will feature an investigation of the ImPrint genomic test, currently for research use only, from the I-SPY trial series and an analysis from FLEX of hormone receptor-positive breast cancer in Black women classified by BluePrint®.

The company believes the FLEX Registry’s approach to cancer research is accelerating impactful data generation, aimed at redefining cancer care. Its patient-centric design and national network of participating sites is backed by Agendia’s infrastructure, allowing its investigator-initiated sub-studies to produce important results that have the potential to drive science forward, like those being shared at ASCO 2022.

Following are details of the nine Agendia abstracts that have been accepted for poster discussion or poster sessions at the ASCO 2022 Annual Meeting:

Poster discussion sessions

The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2

Authors: Kuilman, MM., et al.

Presenter: Lorenza Mittempergher, PhD | Research and Development, Agendia NV

Session: Breast Cancer – Local/Regional/Adjuvant

Poster Discussion: Monday, June 6, 2022 | 1:15 PM-2:45 PM CDT

Abstract #: 514

Whole transcriptomic analysis of HR+ breast cancer in Black women classified as basal-type by BluePrint

Authors: Reid, S., et al.

Presenter: Sonya A. Reid, MD, MPH | Vanderbilt University Medical Center

Session: Breast Cancer – Local/Regional/Adjuvant

Poster Discussion: Monday, June 6, 2022 | 1:15 PM-2:45 PM CDT

Abstract #: 517

Poster sessions

Whole transcriptome analysis of tumors with discordant oncotype and MammaPrint results in the FLEX trial

Authors: Socoteanu, M., et al.

Session: Breast Cancer – Local/Regional/Adjuvant

Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT

Abstract #: 556

Clinical implications for patients with discordant oncotype and MammaPrint results

Authors: Socoteanu, M., et al.

Session: Breast Cancer – Local/Regional/Adjuvant

Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT

Abstract #: 560

Investigation of a genomic signature for transcription factor MAF gene amplification and lack of bisphosphonate benefit in early breast cancer

Authors: Nasrazadani, A., et al.

Session: Breast Cancer – Local/Regional/Adjuvant

Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT

Abstract #: 559

Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy

Authors: Chung, A., et al.

Session: Breast Cancer – Local/Regional/Adjuvant

Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT

Abstract #: 585

Distribution of breast cancer molecular subtypes within receptor classifications: Lessons from the I-SPY2 trial and FLEX Registry

Authors: Cha, J., et al.

Session: Breast Cancer – Local/Regional/Adjuvant

Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT

Abstract #: 592

FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data

Authors: Ma, C., et al.

Session: TBC

Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT

Abstract #: TPS612

Defining transcriptomic profiles of early-stage mucinous breast cancers: A FLEX sub study

Authors: Sivapiragasam, A., et al.

Session: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology

Session Date & Time: Sunday, June 5, 2022 | 8:00 AM-11:00 AM CDT

Abstract #: 3134

Agendia will be sharing important updates on its Twitter, Facebook and LinkedIn pages throughout the conference. The event program can be found at the ASCO 2022 website.

About Agendia

Agendia is a mission-driven, commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.

MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of the biology underlying an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan.

For more information on Agendia’s assays and ongoing trials,

This material is not a CNA editorial material and CNA shall not bear responsibility for the accuracy of its content. In case you have any questions about the content, kindly refer to the contact person mentioned in the text of the press release.

Source: Cyprus News Agency